iGIANT was developed by Saralyn Mark, MD at the White House Office of Science and Technology Policy and was launched a the Department of Health and Human Services Office (DHHS) of the White House. In early Summer of 2015, the Office on Women’s Health within the DHHS hosted the iGIANT (Impact of Gender/Sex on Innovation and Novel Technologies) roundtable for organizations that have or are in the process of developing a gender/sex-specific product, program, policy or protocol related to health.
Agencies and organizations, including the National Institutes of Health and NASA, have policies on the inclusion of gender and sex in research studies. Men and women can present with different disease symptoms, courses and responses to therapeutics. Understanding the impact of gender and sex on health can enhance precision medicine as well as disease prevention and health promotion strategies. The time has come to move from the research bench to the design of gender/sex-specific products, programs, polices or protocols related to health.
In the first iGIANT event in Chicago, 10 presenters shared real world economic implications of gender and sex in healthcare, technology, law and innovation.